COVID-19 in elderly: Correlations of viral load, clinical course, laboratory parameters, among patients vaccinated with CoronaVac

Acta Microbiol Immunol Hung. 2022 Nov 11;69(4):277-282. doi: 10.1556/030.2022.01849. Print 2022 Dec 6.

Abstract

SARS-CoV-2 virus was initially identified in Wuhan, China, in December 2019 and a global pandemic was declared in March 2020 by World Health Organization. COVID-19 disease is characterized with severe pneumonia and hypoxemia, especially in the elderly population. The elderly population was primarily vaccinated with CoronaVac, which is a whole virion inactivated vaccine (Sinovac Biotech, China) in Turkey. This study aimed to investigate the association of viral load and laboratory parameters with the severity of the disease and vaccination status in elderly (older than 60 years old) COVID-19 patients. The age range of the patients was 61-97 years old with a mean of 71.80. Vaccinated patients had a lower viral load (P = 0.253) in nasopharyngeal swabs during breakthrough COVID-19 infection compared to unvaccinated ones and were hospitalized for a shorter period of time in hospital wards (P = 0.035). A lower number of patients were vaccinated in both moderate (n = 33, 29.20%) and severe/critical group (n = 46, 34.07%) (P = 0.412). Only 17 (32.08%) vaccinated patients were hospitalized in an intensive care unit (ICU), whereas 36 (67.92%) of the ICU patients were unvaccinated (P = 0.931). Severe/critical patients had higher c-reactive protein (CRP), platelet-to-lymphocyte ratio (PLR), fibrinogen, ferritin, and lactate dehydrogenase (LDH) levels compared to the moderate group on the admission day (P < 0.05). Our study suggested that elderly patients vaccinated with CoronaVac had a shorter stay in hospitals and according to our results CRP, PLR, fibrinogen, ferritin, and LDH levels could be used to determine the severity of the infections.

Keywords: COVID-19; CoronaVac; elderly; hospitalization; viral load.

MeSH terms

  • Aged
  • Aged, 80 and over
  • COVID-19* / prevention & control
  • Disease Progression
  • Fibrinogen
  • Humans
  • Middle Aged
  • SARS-CoV-2
  • Viral Load

Substances

  • sinovac COVID-19 vaccine
  • Fibrinogen

Supplementary concepts

  • COVID-19 breakthrough infections